Tag:
hepatitis B
Latest Headlines
Latest Headlines
Study: Obesity can blunt effectiveness of hep B vaccine
An epidemic of obesity in American teens is forcing clinicians to reconsider how they vaccinate young people. A new study says that obese teens will need longer needles if they're to be effectively
Dynavax gets green light to resume hep B vax program
The FDA is giving Dynavax Technologies a green light to resume testing of a late-stage hepatitis B vaccine that had been derailed 18 months ago after a patient in one study developed a rare
Dynavax shares soar as FDA clears hep B trial
Over at FierceVaccines this morning, we take a look at several key biotech developments. Dynavax Technologies' shares soared 75 percent after the FDA lifted its clinical hold on the developer's
Dynavax explores new strategy for Heplisav
Dynavax Technologies has been talking with regulators in Europe about the potential for developing Heplisav, an experimental hepatitis B vaccine, for people over 40 who aren't responding to currently
Merck reports hep B vaccine shortage
Equipment upgrades at Merck's West Point, PA-based vaccine plant will cause shortages of its hepatitis B vaccine Recombivax HB for adults. The company said that pediatric doses would not be effected.
Nanotech hep B vaccine could revolutionize therapy
Scientists at the University of Michigan are moving closer to human trials of a new nanoemulsion hepatitis B vaccine that could revolutionize therapy in the third world. The nanoemulsion approach
Merck, Dynavax announce Heplisav results
Dynavax and Merck announced that their hepatitis B vaccine Heplisav achieved the primary endpoint in a Phase III study. In the study, 95.1 percent of subjects who received Heplisav developed
Merck, Dynavax announce Heplisav results
Dynavax and Merck announced that their hepatitis B vaccine Heplisav achieved the primary endpoint in a Phase III study. In the study, 95.1 percent of subjects who received Heplisav developed
ALSO NOTED: New vaccine/chemo combo effective in cancer study; Type 1 diabetes vaccine goes into human studies; and much more..
> Chutes & Ladders: Susan Windham-Bannister will take over as CEO of the Massachusetts Life Sciences Center Board. The board's function is to ensure the state retains its prominence in the
Dynavax drops Tolamba on trial failure
Dynavax is dropping it's mid-stage ragweed allergy drug Tolamba as it failed to meet its primary efficacy endpoint. While the drug showed a measurable clinical benefit, reducing total nasal symptom
